{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002874","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.752058+00:00","generated_at":"2026-05-28T02:39:48.667550+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel reports prelim Q4 total revenue $57.6M, guides FY2025 rev $200-210M","bullets":["Q4 2024 total revenue $57.6M vs $35.8M Q4 2023; net product sales $46.5M.","TAVALISSE net sales $31.0M, REZLIDHIA $7.4M, GAVRETO $8.1M (launched June 2024).","Full-year 2024 total revenue $179.3M; cash & equivalents $77.3M at year-end.","2025 guidance: total revenue $200-210M; expects positive net income for the year.","R289 granted Orphan Drug designation by FDA for MDS; Phase 1b enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002874","json":"https://secwatch.observer/filing/0001104659-25-002874.json","markdown":"https://secwatch.observer/filing/0001104659-25-002874.md","text":"https://secwatch.observer/filing/0001104659-25-002874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925002874/0001104659-25-002874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925002874/tm253048d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:39:48.667550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}